Fed. Circ. Erases Amgen Win Over Sanofi Cholesterol Drug
In a battle involving next-generation cholesterol drugs, the Federal Circuit on Thursday nullified Amgen's patent win over Sanofi and Regeneron Pharmaceuticals, concluding that a district judge wrongly excluded evidence and botched...To view the full article, register now.
Already a subscriber? Click here to view full article